-
T-DXd Meaningfully Improves PFS Vs Chemo in HR+, HER2-Low Breast Cancer
30 Apr 2024 03:02 GMT
… HR-positive breast cancer, further redefining the treatment of metastatic breast cancer.”
In … advanced or metastatic, HER2-low or HER2-negative, HR-positive breast cancer … low, hormone receptor positive, metastatic breast cancer (DB-06). ClinicalTrials.gov. …
-
Enhertu delays disease progression in certain patients with metastatic breast cancer
29 Apr 2024 20:27 GMT
… or HER2-ultralow advanced or metastatic breast cancer who received a … ]-positive breast cancer, further redefining the treatment of metastatic breast cancer.”
The … researchers remained consistent with previous breast cancer clinical trials. Complete results …
-
Truqap Plus Faslodex Recommended for Approval in the EU by CHMP for Advanced ER-Positive Breast Cancer
29 Apr 2024 16:41 GMT
… , HER2‑negative locally advanced or metastatic breast cancer with one or more … of patients with advanced HR-positive breast cancer. HR-positive breast cancer progression is … therapies in patients with advanced ER-positive breast cancer to delay disease …
-
Double Good News For AstraZeneca's Breast Cancer Drugs
29 Apr 2024 14:37 GMT
… topline data from a metastatic breast cancer treatment study.
The results showed … >0<1+] metastatic breast cancer).
Related: AstraZeneca Posts Bumper Earnings … )-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more …
-
AstraZeneca's Truqap Plus Faslodex Recommended For EU Approval By CHMP For Advanced Breast Cancer
29 Apr 2024 06:51 GMT
… )-positive, HER2-negative locally advanced or metastatic breast cancer with one or more …
-
AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial
29 Apr 2024 10:24 GMT
… HR-positive, HER2-low metastatic breast cancer.
Enhertu is a specifically … ISH-) or HER2-ultralow advanced or metastatic breast cancer.
The trial also indicated … HR-positive breast cancer, further redefining the treatment of metastatic breast cancer.”
The …
-
AstraZeneca makes progress with two breast cancer treatments
29 Apr 2024 09:02 GMT
… , HER2‑negative locally advanced or metastatic breast cancer who had experienced recurrence … prevalence of HR-positive breast cancer and the frequency of … HR-positive breast cancer, further redefining the treatment of metastatic breast cancer.”
Reporting …
-
Astrazeneca: London-listed pharma giant heralds successful new breast cancer drug
29 Apr 2024 08:31 GMT
… -low and HER2-ultralow metastatic breast cancer.”
“These data underscore the potential … HR-positive breast cancer, further redefining the treatment of metastatic breast cancer,” she added … with a specific type of advanced breast cancel.
It comes after …
-
Stromal B Lymphocytes Affecting Prognosis in Triple-Negative Breast Cancer by Opal/TSA Multiplexed Immunofluorescence
29 Apr 2024 08:25 GMT
… -line treatment of unresectable locally advanced or metastatic PD-L1 positive … . Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1 … 8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat. 2013;137 …
-
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
29 Apr 2024 06:14 GMT
… >0 <1+]) advanced or metastatic breast cancer. Patients in the trial … had no prior chemotherapy for advanced … ClinicalTrials.gov.
About Breast Cancer and HER2 Expression
Breast cancer is the second most …